Lake Pointe Operating Company, LLC

Lake Pointe Operating Company, LLC was paid $9.44M by Medicaid between Jan 2020 and Dec 2024, across 92 billing codes. Its largest line is 99284, emergency room visit (serious) — 56% of everything it billed.

33Billing provider infoLAKE POINTE OPERATING COMPANY, LLC
ROWLETT, TX 75088

33aNPI1205018439assigned 11/29/2007

33bProvider typeGeneral Acute Care Hospital

28Total paid$9.44M

24GClaims158,902

24DCodes billed92

24AFirst – last monthJan 2020 – Dec 2024

Compared with peers

Next to other General Acute Care Hospital providers in Texas

Rank by total paid#17 of 109

Median peer was paid$1.15M

This provider vs. median8.2×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	3,104	$89K
2021	28,855	$1.60M
2022	47,419	$3.57M
2023	51,543	$2.82M
2024incomplete	27,981	$1.36M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	56%	23,124	21,510	$5.27M
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	7.2%	11,709	10,799	$676K
99282	Emergency department visit for the evaluation and management, low to moderate severity	6.8%	11,886	11,010	$646K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	6.4%	9,957	9,361	$600K
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	4.1%	1,644	1,476	$389K
74177	Computed tomography, abdomen and pelvis; with contrast material	2.9%	1,025	948	$277K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	2.1%	360	338	$201K
80053	Comprehensive metabolic panel	1.7%	11,406	9,474	$164K
70450	Computed tomography, head or brain; without contrast material	1.3%	1,230	1,126	$119K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	1.2%	3,130	2,707	$116K
71045	Radiologic examination, chest; single view	1.1%	3,468	3,104	$105K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.0%	11,269	9,173	$98K

80 more codes

74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	493	$75K
87430		<1%	3,765	$65K
96361	Intravenous infusion, hydration; each additional hour	<1%	468	$61K
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	<1%	273	$59K
84484		<1%	2,852	$36K
83880		<1%	1,098	$34K
81025		<1%	3,796	$32K
87086	Culture, bacterial; quantitative colony count, urine	<1%	3,766	$30K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	778	$27K
87070		<1%	2,014	$26K
71046	Radiologic examination, chest; 2 views	<1%	643	$25K
72125	Computed tomography, cervical spine; without contrast material	<1%	228	$24K
87486		<1%	360	$21K
76801		<1%	237	$20K
87581		<1%	360	$20K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	360	$19K
83690		<1%	2,773	$14K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	1,438	$13K
81001		<1%	3,544	$12K
36415	Collection of venous blood by venipuncture	<1%	12,026	$12K
71275	Computed tomographic angiography, chest, with contrast material	<1%	78	$12K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	236	$11K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	355	$9K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	220	$9K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	220	$9K
81003		<1%	2,903	$7K
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	93	$7K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	474	$7K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	209	$7K
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	146	$6K
87420		<1%	160	$5K
84702		<1%	569	$4K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	1,270	$4K
87077		<1%	471	$4K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	235	$4K
85610		<1%	994	$3K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	21	$3K
85730		<1%	675	$3K
87186		<1%	436	$3K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	48	$3K
J2270	Injection, morphine sulfate, up to 10 mg	<1%	1,099	$2K
85379		<1%	266	$2K
83605		<1%	215	$2K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	100	$2K
84703		<1%	306	$2K
96375	Therapeutic injection; each additional sequential IV push	<1%	752	$2K
86900		<1%	602	$2K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	1,116	$2K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	2,199	$2K
85027		<1%	303	$2K
80048	Basic metabolic panel (calcium, ionized)	<1%	185	$1K
86901		<1%	505	$1K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	871	$1K
84443	Thyroid stimulating hormone (TSH)	<1%	71	$1K
83735		<1%	146	$1K
96376		<1%	198	$1K
87210		<1%	173	$1K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	2,640	$986.48
74018		<1%	13	$931.68
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	34	$878.61
93976		<1%	16	$732.41
73130		<1%	14	$710.92
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	898	$689.93
85007		<1%	203	$610.97
87081		<1%	117	$354.39
J2272	Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg	<1%	181	$344.55
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	325	$326.82
J1170	Injection, hydromorphone, up to 4 mg	<1%	26	$191.61
87040		<1%	14	$156.24
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	153	$96.82
86850		<1%	13	$67.13
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	31	$24.13
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	173	$23.77
82962		<1%	1,067	$22.64
J2550	Injection, promethazine hcl, up to 50 mg	<1%	13	$3.45
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	0%	2,378	$0.00
36592		0%	20	$0.00
J8540	Dexamethasone, oral, 0.25 mg	0%	128	$0.00
J2003	Injection, lidocaine hydrochloride, 1 mg	0%	27	$0.00
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	0%	18	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCOLE, DONAS (CEO)